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Abstract
While primary percutaneous coronary intervention (PCI) has significantly contributed to improve the mortality in patients 
with ST segment elevation myocardial infarction even in cardiogenic shock, primary PCI is a standard of care in most of 
Japanese institutions. Whereas there are high numbers of available facilities providing primary PCI in Japan, there are no 
clear guidelines focusing on procedural aspect of the standardized care. Whilst updated guidelines for the management 
of acute myocardial infarction were recently published by European Society of Cardiology, the following major changes 
are indicated; (1) radial access and drug-eluting stent over bare metal stent were recommended as Class I indication, and 
(2) complete revascularization before hospital discharge (either immediate or staged) is now considered as Class IIa rec-
ommendation. Although the primary PCI is consistently recommended in recent and previous guidelines, the device lag 
from Europe, the frequent usage of coronary imaging modalities in Japan, and the difference in available medical therapy 
or mechanical support may prevent direct application of European guidelines to Japanese population. The Task Force on 
Primary Percutaneous Coronary Intervention of the Japanese Association of Cardiovascular Intervention and Therapeutics 
(CVIT) has now proposed the expert consensus document for the management of acute myocardial infarction focusing on 
procedural aspect of primary PCI.
Keywords ST elevation acute myocardial infarction · Acute coronary syndrome · Plaque rupture · Plaque erosion · 
Percutaneous ventricular assist devices · Guideline
Introduction
In ST segment elevation myocardial infarction (STEMI), 
primary PCI has been shown to reduce cardiac events, 
to convey earlier discharge and to contribute to hemody-
namic stabilization in cardiogenic shock and subsequently 
to become a standard care in Japan [1–19]. Despite a high 
number of available facilities providing primary PCI in 
Japan, there are no guidelines focusing on procedural aspect 
of standardized care, which may further improve the quality 
of our practice.
Recently, updated guidelines for the management of acute 
myocardial infarction (AMI) were published by European 
Society of Cardiology (ESC) [20]. As major changes, (1) 
radial access and drug-eluting stent (DES) over bare metal 
stent (BMS) were recommended as Class I indication, (2) 
complete revascularization before hospital discharge (either 
immediate or staged) is now considered as Class IIa recom-
mendation. The primary PCI is consistently recommended 
in the updated guidelines as well as the previous guidelines 
[21].
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However, the device lag between Europe and Japan, the 
difference in available medical therapy and mechanical sup-
port may prevent direct application of European guidelines 
to Japanese population (Tables 1, 2). Therefore, the Task 
Force on Primary Percutaneous Coronary Intervention (PCI) 
of the Japanese Association of Cardiovascular Intervention 
and Therapeutics (CVIT) summarized the expert consensus 
for the management of acute myocardial infarction, mainly 
focusing on procedural aspect.
Specific differences between Japan and Europe 
(Table 1)
For example, glycoprotein (GP) IIb/IIIa inhibitors are not 
available in Japan, where thrombus aspiration is still a first 
choice of strategy of treatment of AMI.
Currently preferred oral P2Y12 inhibitors in acute 
coronary syndrome (ACS) in Europe are prasugrel and 
ticagrelor. Although ticagrelor became available recently 
Table 1  Major differences in available medication and mechanical devices
Europe Japan
Glycoprotein IIb/IIIa inhibitors Tirofiban, eptifibatide, and abciximab are available GP IIb/IIIa inhibitors are not available
P2Y12 inhibitors The preferred P2Y12 inhibitors are prasugrel [60 mg 
loading dose and 10 mg maintenance dose once 
daily per os (p.o.)] or ticagrelor (180 mg p.o. load-
ing dose and 90 mg maintenance dose twice daily)
Both prasugrel and ticagrelor are available, but the dose 
in prasugrel is different. [20 mg loading dose and 
3.75 mg maintenance dose once daily per os]
Mechanical LV assist devices Intra-cardiac axial flow pump (i.e. Impella) and intra-
aortic balloon pump are available
Intra-aortic balloon pump is used. Intra-cardiac axial 
flow pump (i.e. Impella) is not widely available but 
used in limited institutions
Table 2  Major CE approved 
DES and their availability in 
Japan
DES Stent platform Polymer coating Drug Avail-
ability in 
Japan
Based on durable polymer coatings
 DESyne Nx Cobalt-chrome PBMA Novolimus No
 Promus element Platinum-chrome PBMA and PVDF-HFP Everolimus Yes
 Resolute Cobalt-chrome PBMA, PHMA, PVP, and PVA Zotarolimus Yes
 STENTYS Nitinol PSU and PVP Paclitaxel No
 Xience Cobalt-chrome PBMA and PVDF-HFP Everolimus Yes
Based on biodegradable polymer coatings
 Axxess Nitinol PDLLA Biolimus A9 No
 Biomatrix Stainless steel PDLLA Biolimus A9 No
 BioMime Cobalt-chrome PLLA and PLGA Sirolimus No
 Combo Stainless steel PDLLA and PLGA + addi-
tional coating with anti-CD34
Sirolimus No
 DESyne BD Cobalt-chrome PLLA Novolimus No
 Infinnium Stainless steel PLLA, PLGA, PCL, and PVP Paclitaxel No
 MiStent Cobalt-chrome PLGA Crystalline sirolimus No
 Nobori Stainless steel PDLLA Biolimus A9 Yes
 Orsiro Cobalt-chrome PLLA Sirolimus Yes
 Supralimus Core Cobalt-chrome PLLA, PLGA, PCL, and PVP Sirolimus No
 Synergy Platinum-chrome PLGA Everolimus Yes
 Ultimaster Cobalt-chrome PDLLA and PCL Sirolimus Yes
 Yukon Choice PC Stainless steel PDLLA Sirolimus No
Polymer-free
 Amazonia Pax Cobalt-chrome – Paclitaxel No
 BioFreedom Stainless steel – Biolimus A9 Yes
 Cre8 Cobalt-chrome – Sirolimus No
 Yukon Choice PF Stainless steel – Sirolimus No
 Coroflex ISAR Cobalt-chrome – Sirolimus No
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in Japan, it was approved in 2016 and put on the market 
in February 2017, with a 7-year lag from the approval in 
Europe. In addition, dose difference in P2Y12 inhibitors 
between Japan and Europe may cause different anti-throm-
botic benefit/bleeding risk profile. Intravenous cangrelor 
is not approved in Japan, while its use may be considered 
in patients not pre-treated with oral P2Y12 inhibitors at 
the time of PCI or in those who are considered unable to 
absorb oral agents in Europe.
LV assist devices and ECMO are increasingly popu-
lar managing patients with cardiogenic shock in Europe 
although they have not been sufficiently evaluated in clini-
cal trials, while the use of IABP has not met prior expecta-
tions of benefit [22, 23]. In contrast, left ventricular assist 
devices (LVADs, i.e. intra-cardiac axial flow pumps and 
arterial-venous extracorporeal membrane oxygenation) are 
not widely available in Japanese institutions, while percu-
taneous ventricular assist devices (Impella) has recently 
been approved in limited institution in Japan where we 
largely rely on intra-aortic balloon pump as a mechanical 
support.
Regarding intravascular imaging devices, intravascular 
ultrasound and optical coherence tomography during PCI 
are routinely reimbursed in Japan. On the contrary to the 
situation in Europe and United States of America, its use 
is not restricted in selected cases such as unprotected left 
main lesions or stent failure.
In terms of data derived from Japanese population, 
there are several registries including patients with AMI 
in Japan such as J-MINUET [24, 25], PACIFIC [26], 
and Tokyo CCU network registry [27]. CVIT has been 
working on J-PCI registry [28–31], a largest database of 
Table 3  Demographics of patients with STEMI and NSTEMI from J-PCI registry
Data are counts (percentage) unless otherwise specified
CABG coronary artery bypass grafting, IQR interquartile range, MI myocardial infarction, NSTEMI non ST-elevation myocardial infarction, PCI 
percutaneous coronary intervention, STEMI ST-elevation myocardial infarction
Overall MI (n = 53240) STEMI (n = 41774) NSTEMI (n = 11466) P value 
(STEMI vs. 
NSTEMI)
Age (years), mean (SD) 68.78 (12.84) 68.47 (12.93) 69.92 (12.43) < 0.001
Female 12856 (24.1) 10066 (24.1) 2790 (24.3) 0.609
Cardiogenic shock 6076 (11.5) 5128 (12.4) 948 (8.3) < 0.001
Risk factors
 Current smoker 20455 (38.4) 16396 (39.2) 4059 (35.4) < 0.001
 Diabetes mellitus 18905 (35.5) 14300 (34.2) 4605 (40.2) < 0.001
 Hypertension 35656 (67.0) 27463 (65.7) 8193 (71.5) < 0.001
 Hypercholesterolemia 30113 (56.6) 23166 (55.5) 6947 (60.6) < 0.001
History of
 Previous MI 7202 (13.6) 4874 (11.8) 2328 (20.4) < 0.001
 Peripheral vascular disease 1841 (3.5) 1230 (2.9) 611 (5.3) < 0.001
 Previous PCI 9384 (17.7) 6453 (15.5) 2931 (25.6) < 0.001
 Previous CABG 772 (1.5) 418 (1.0) 354 (3.1) < 0.001
 Heart failure 3644 (7.0) 2280 (5.5) 1364 (12.0) < 0.001
 Renal insufficiency 7401 (13.9) 5359 (12.8) 2042 (17.8) < 0.001
 Chronic lung disease (COPD) 1151 (2.2) 859 (2.1) 292 (2.5) 0.002
Door to balloon time
 Min, median (IQR 25th, 75th) 71 (54, 91) 71 (54, 91) NA NA
Antiplatelet prescribed before or at procedure
 Dual antiplatelet therapy
 Aspirin + clopidogrel 8085 (19.5) 5749 (18.0) 2336 (24.9) < 0.001
 Aspirin + ticagrelor 29 (0.1) 25 (0.1) 4 (0.0) 0.356
 Aspirin + prasugrel 27351 (66.0) 21688 (67.7) 5663 (60.3) < 0.001
 Single antiplatelet therapy 5404 (13.0) 4167 (13.0) 1237 (13.2) 0.719
 None 12038 (22.6) 9935 (23.8) 2103 (18.3) < 0.001
In-hospital mortality 1314 (2.5) 1090 (2.6) 224 (2.0) < 0.001
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patients who underwent PCI in Japan. The current demo-
graphics, lesion and procedural characteristics in patients 
with AMI in Japan can be identified in the J-PCI registry 
(Tables 3, 4) [from a database including 243436 patients 
treated in 986 institutions from January 2016 to Decem-
ber 2016]. 
Primary PCI in STEMI, early invasive vs. 
conservative strategy in NSTEMI
In ST segment elevation myocardial infarction, primary PCI 
has been shown to contribute high revascularization success 
rate, less cardiac events, earlier discharge, even effective in 
patients with cardiogenic shock [1–19] and consistently rec-
ommended by European [20], American [32], and Japanese 
guidelines.
Regarding non-ST-segment elevation acute coronary 
syndrome (NSTE-ACS), meta-analysis, based on individual 
patient data from three studies that compared a routine inva-
sive against a selective invasive strategy, revealed lower rates 
of death and myocardial infarction at 5-year follow-up in 
the routine invasive strategy (HR 0.81; 95% CI 0.71–0.93; 
P = 0.002), with the most pronounced difference in high-
risk patients [33]. Age, diabetes, previous myocardial infarc-
tion, ST-segment depression, hypertension, body mass index 
(< 25 or > 35 kg/m2), and treatment strategy were found to 
be independent predictors of death and myocardial infarction 
during follow-up. The results supported a routine invasive 
strategy but highlight the importance of risk stratification in 
the decision-making process management as is in the present 
guidelines.
However, in the ICTUS trial, in which 1200 patients 
with NSTE-ACS and an elevated cardiac troponin T were 
randomized to an early invasive strategy versus a selective 
invasive strategy, 10-year death or spontaneous MI was not 
statistically different between the 2 groups (33.8 vs. 29.0%, 
HR 1.12; 95% CI 0.97–1.46; P = 0.11). In addition, the 
15-year follow-up of the FRISC-II study showed a signifi-
cant 18-month postponement of the occurrence of death or 
next MI and 37 months postponement of re-hospitalisation 
for ischemic heart disease in the early invasive strategy but 
similar mortality with either strategy [34]. Although the 
long-term benefit of an early invasive strategy is unclear, 
Table 4  Lesion and procedural characteristics in STEMI and NSTEMI from J-PCI registry
Data are counts (percentage)
BMS bare metal stent, DES drug-eluting stent, LAD left anterior descending artery, LCx left circumflex artery, MI myocardial infarction, 
NSTEMI non ST-elevation myocardial infarction, RCA right coronary artery, STEMI ST-elevation myocardial infarction, TIMI thrombolysis in 
myocardial infarction
Overall (n = 53240) STEMI (n = 41774) NSTEMI (n = 11466) P value (STEMI 
vs. NSTEMI)
Lesion characteristics
 Lesion location
  LAD/left main 27993 (52.6) 22427 (53.7) 5566 (48.5) < 0.001
  LCX 10730 (20.2) 6642 (15.9) 4088 (35.7) < 0.001
  RCA 20390 (38.3) 16910 (40.5) 3480 (30.4) < 0.001
  Bypass graft 170 (0.3) 76 (0.2) 94 (0.8) < 0.001
Restenotic lesion 2253 (4.2) 1573 (3.8) 680 (5.9) < 0.001
Procedure details
 Approach < 0.001
  Transfemoral 21241 (39.9) 17613 (42.2) 3628 (31.6)
  Transradial 30380 (57.1) 22972 (55.0) 7408 (64.6)
  Others (e.g. brachial) 1619 (3.0) 1189 (2.8) 430 (3.8)
  Thrombus aspiration 25579 (48.0) 22626 (54.2) 2953 (25.8) < 0.001
  Distal protection 3874 (7.3) 3386 (8.1) 488 (4.3) < 0.001
 Stent characteristics
  Type of stent
  DES 45622 (85.7) 35962 (86.1) 9660 (84.2) < 0.001
  BMS 1856 (3.5) 1548 (3.7) 308 (2.7) < 0.001
  Other stent (Scaffold) 62 (0.1) 47 (0.1) 15 (0.1) 0.723
  No stent used 5876 (11.0) 4352 (10.4) 1524 (13.3) < 0.001
 TIMI flow post-procedure
  Flow 3 52122 (97.9) 40969 (98.1) 11153 (97.3) < 0.001
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the timing of angiography and revascularization should be 
based on patient risk profile, considering the significant 
difference between early and delayed strategies in short-
term outcome.
Recently, GRACE risk score was applied to the patients 
with ACS in the Tokyo CCU (cardiovascular care unit) 
Network Database. A total of 9460 patients with ACS 
hospitalized at 67 Tokyo CCUs were retrospectively 
reviewed and there was a strong correlation between the 
GRACE risk score and in-hospital mortality for patients 
with STEMI or NSTEMI (r = 0.99, P < 0.001); however, 
the correlation was not significant for patients with unsta-
ble angina (r = 0.35, P = 0.126). We recommend use of 
GRACE score to identify high-risk patients with acute 
myocardial infarction [35].
Recommendations
• Primary PCI of the infarct-related artery (IRA) is indi-
cated in STEMI.
In case of NSTEMI
• Urgent coronary angiography (< 2 h) is recommended 
in patients at very high ischemic risk (refractory angina, 
with associated heart failure, cardiogenic shock, life-
threatening ventricular arrhythmias, or hemodynamic 
instability).
• An early invasive strategy (< 24 h) is recommended in 
patients with at least one primary high-risk criterion 
(Table 5).
• An invasive strategy (< 72 h after first presentation) is 
indicated in patients with at least one high-risk criterion 
(Table 5) or recurrent symptoms.
• Non-invasive documentation of inducible ischemia is rec-
ommended in low-risk patients without recurrent symp-
toms before deciding on invasive evaluation.
Practical recommendation for primary 
percutaneous coronary intervention
Loading dose DAPT
Prasugrel and ticagrelor reduce ischemic events and mortal-
ity in ACS patients compared to clopidogrel and are recom-
mended by current guidelines [20, 36].
In TRITON-TIMI 38, 13608 patients with acute coro-
nary syndromes with scheduled percutaneous coronary 
intervention were randomized to either prasugrel or clopi-
dogrel. Prasugrel therapy was associated with significantly 
reduced rates of ischemic events, including stent thrombo-
sis, but with an increased risk of major bleeding, including 
fatal bleeding. Overall mortality did not differ significantly 
between treatment groups [36]. In Japanese population, the 
PRASFIT-ACS study was conducted to confirm the effi-
cacy and safety of prasugrel at loading/maintenance doses 
of 20/3.75 mg [37]. Japanese patients (n = 1363) with acute 
coronary syndrome undergoing percutaneous coronary inter-
vention were randomized to either prasugrel (20 mg for load-
ing/3.75 mg for maintenance) or clopidogrel (300 mg for 
loading/75 mg for maintenance). The incidence of MACE 
at 24 weeks was 9.4% in the prasugrel group and 11.8% 
in the clopidogrel group (risk reduction 23%, hazard ratio 
0.77, 95% confidence interval 0.56–1.07). The incidence of 
non-coronary artery bypass graft-related major bleeding was 
similar in both groups (1.9 vs. 2.2%). The results were simi-
lar to TRITON-TIMI 38 with a low risk of clinically serious 
bleeding in Japanese ACS patients.
Regarding ticagrelor, clinical outcomes in a large real-
world post-ACS population was studied in a Swedish pro-
spective cohort study in 45073 ACS patients who were dis-
charged on ticagrelor (N = 11954) or clopidogrel (N = 33119) 
[38]. The risk of the primary outcome (i.e. composite of 
all-cause death, re-admission with Ml or stroke) with tica-
grelor vs. clopidogrel was 11.7 vs. 22.3% [adjusted HR 
(HR) 0.85 (95% CI 0.78–0.93)], risk of death 5.8 vs. 12.9% 
[adjusted HR 0.83 (0.75–0.921)], and risk of Ml 6.1 vs. 
10.8% [adjusted HR 0.89 (0.78–1.011)] at 24 months. Re-
admission for bleeding with ticagrelor versus clopidogrel 
was similar. Ticagrelor versus clopidogrel post-ACS was 
associated with a lower risk of death, Ml, or stroke, as well 
as death alone. Risk of bleeding was higher with ticagre-
lor [38]. These real-world outcomes are consistent with the 
Table 5  Criteria for high risk with indication for invasive manage-
ment [20]
CABG coronary artery bypass grafting, eGFR estimated glomerular 
filtration rate, GRACE Global Registry of Acute Coronary Events, LV 
left ventricular, PCI percutaneous coronary intervention
Primary criteria
 1. Relevant rise or fall in troponin
 2. Dynamic ST- or T-wave changes (symptomatic or silent)
 3. GRACE score > 140
Secondary criteria
 4. Diabetes mellitus
 5. Renal insufficiency (eGFR < 60 ml/min/1.73 m2)
 6. Reduced LV function (ejection fraction < 40%)
 7. Early post-infarction angina
 8. Recent PCI
 9. Prior CABG
 10. Intermediate to high GRACE risk score (http://www.grace score 
.org)
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results of the landmark Platelet Inhibition and Patient Out-
comes (PLATO) trial [39].
Both prasugrel and ticagrelor are available for clinical use 
in Japan as well. While the recommended dose of prasugrel 
is the same as in Europe and United States of America, the 
Japanese dose of prasugrel was reduced according to the 
PLASFIT-ACS study [37] (EU: 60 mg loading dose and 
10 mg maintenance dose once daily; Japan: 20 mg loading 
dose and 3.75 mg maintenance dose once daily) (Table 1).
Recommendations
• A potent P2Y12 inhibitor (prasugrel or ticagrelor), or 
clopidogrel if these are not available or are contraindi-
cated, is recommended before (or at latest at the time 
of) PCI and maintained over 12 months, unless there are 
contraindications such as excessive risk of bleeding.
• Recommended dose of prasugrel: 20 mg loading dose 
and 3.75 mg maintenance dose once daily per os (p.o.).
• Recommended dose of ticagrelor: 180 mg p.o. loading 
dose and 90 mg maintenance dose twice daily.
Anticoagulation during PCI
According to the 2017 ESC STEMI Guidelines, routine use 
of unfractionated heparin (UFH) is recommended as a Class 
I recommendation and routine use of enoxaparin or bivaliru-
din during primary PCI is a Class IIa recommendation [20].
There has been no placebo-controlled trial evaluating 
UFH in primary PCI, but there is a large body of experience 
with this agent. Dosage should follow standard recommen-
dations for PCI (i.e. initial bolus 70–100 U/kg). There are 
no robust data recommending the use of activated clotting 
time to tailor dose or monitor UFH, and if activated clotting 
time is used, it should not delay recanalization of the IRA.
An i.v. bolus of enoxaparin 0.5 mg/kg was compared with 
UFH in the ATOLL randomized trial including 910 STEMI 
patients [40]. The primary composite endpoint of 30 day 
death, MI, procedural failure, or major bleeding was not sig-
nificantly reduced by enoxaparin (17% relative risk reduc-
tion, P = 0.063), but there was a reduction in the composite 
main secondary endpoint of death, recurrent MI or ACS, or 
urgent revascularization. Importantly, there was no evidence 
of increased bleeding following the use of enoxaparin over 
UFH. In a meta-analysis of 23 PCI trials (30966 patients, 
33% primary PCI), enoxaparin was associated with a sig-
nificant reduction in death compared to UFH. This effect 
was particularly significant in the primary PCI context and 
was associated with a reduction in major bleeding [41]. In 
Japan, enoxaparin is approved only for subcutaneous and is 
practically difficult to use during PCI.
A meta-analysis comparing bivalirudin with unfraction-
ated heparin (UFH) with or without planned use of GP IIb/
IIIa inhibitors in patients with STEMI showed no mortality 
advantage with bivalirudin and a reduction in the risk of 
major bleeding, but at the cost of an increased risk of acute 
stent thrombosis [42]. In the recent MATRIX trial including 
7213 ACS patients (56% with STEMI), bivalirudin did not 
reduce the incidence of the primary endpoint (composite 
of death, MI, or stroke) compared to UFH. Bivalirudin was 
associated with lower total and cardiovascular mortality, 
lower bleeding, and more definite stent thrombosis [43]. A 
post hoc analysis suggested that prolonging bivalirudin with 
a full-PCI dose after PCI was associated with the lowest 
risk of ischemic and bleeding events, which is in accordance 
with the current label of the drug [43]. Bivalirudin could be 
considered in STEMI, especially in patients at high bleeding 
risk [44–46]. Bivalirudin is recommended for patients with 
heparin-induced thrombocytopenia.
After the publication of the 2017 ESC guidelines, the 
VALIDATE-SWEDEHEART (Bivalirudin versus Heparin 
in ST-Segment and Non-ST-Segment Elevation Myocardial 
Infarction in Patients on Modern Antiplatelet Therapy in 
the Swedish Web System for Enhancement and Develop-
ment of Evidence-based Care in Heart Disease Evaluated 
according to Recommended Therapies Registry Trial) mul-
ticenter, randomized, registry-based trial was published [47]. 
Patients with either ST-segment elevation Ml (N = 3005) or 
non ST-segment elevation Ml (N = 3001) undergoing PCI 
and receiving a potent P2Y12 inhibitor (ticagrelor, prasu-
grel, or cangrelor) without the planned use of glycoprotein 
IIb/IIIa inhibitors were randomly assigned to receive bivali-
rudin or heparin during PCI performed predominantly with 
the use of radial artery access. The primary composite end 
point (death from any cause, Ml, or major bleeding during 
180 days of follow-up) occurred in 12.3% of the patients in 
the bivalirudin group and in 12.8% in the heparin group (HR 
0.96; 95% CI 0.83–1.10; P = 0.54). The results were con-
sistent between patients with ST-segment elevation Ml and 
those with non ST-segment elevation Ml and across other 
major subgroups. There was no difference between groups 
in Ml, major bleeding, definite stent thrombosis or mortal-
ity. This study shows overall clinical non-inferiority for use 
of bivalirudin or heparin during PCI for ACS, along with 
increased cost with use of bivalirudin. Consistently with 
these findings, the current uptake of bivalirudin in Europe 
is very low. Bivalirudin remains unavailable in Japan with 
no evaluation by clinical trials.
Glycoprotein (GP) IIb/IIIa inhibitors are the strongest 
antiplatelet agents currently available in Europe and in the 
US, but are not available in Japan. There are three different 
compounds, namely abciximab, tirofiban, and eptifibatide. 
However, procedural use of abciximab plus unfractionated 
heparin (UFH) showed no benefit compared to bivalirudin 
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[44]. In Japan, JEPPORT randomized, placebo-controlled 
trial (n = 973) did not show efficacy of abciximab in reduc-
ing the primary endpoint (30-day post-PCI coronary events: 
death, MI or urgent revascularization) [48]. However, using 
GP IIb/IIIa inhibitors as bailout therapy in the event of angi-
ographic evidence of a large thrombus, slow- or no-reflow, 
and other thrombotic complications is reasonable, as recom-
mended in 2017 ESC guidelines [20], although this strategy 
has not been tested in a randomized trial. Overall, there is 
no evidence to recommend the routine use of GP IIb/IIIa 
inhibitors for primary PCI.
Recommendations
• Anticoagulation is recommended for all patients in addi-
tion to antiplatelet therapy during primary PCI.
• Routine use of unfractionated heparin (UFH) is recom-
mended.
Approach (femoral vs. radial)
Over recent years, several studies have provided robust evi-
dence in favor of the radial approach as the default access 
site in ACS patients undergoing primary PCI by experi-
enced radial operators [49, 50]. In the Minimizing Adverse 
Hemorrhagic Events by TRansradial Access Site and Sys-
temic Implementation of angioX (MATRIX) programme 
patients were randomized to radial or femoral access, strati-
fied by STEMI (2001 radial, 2009 femoral) and NSTE-
ACS (2196 radial, 2198 femoral). MACE occurred in 121 
(6.1%) STEMI patients with radial access vs. 126 (6.3%) 
patients with femoral access [rate ratio (RR) 0.96, 95% CI 
0.75–1.24; P = 0.76] and in 248 (11.3%) NSTE-ACS patients 
with radial access vs. 303 (13.9%) with femoral access (RR 
0.80, 95% CI 0.67–0.96; P = 0.016) (Pint = 0.25). NACE 
occurred in 142 (7.2%) STEMI patients with radial access 
and in 165 (8.3%) patients with femoral access (RR 0.86, 
95% CI 0.68–1.08; P = 0.18) and in 268 (12.2%) NSTE-ACS 
patients with radial access compared with 321 (14.7%) with 
femoral access (RR 0.82, 95% CI 0.69–0.97; P = 0.023) 
(Pint = 0.76). All-cause mortality and access site-actionable 
bleeding favored radial access irrespective of ACS type 
(Pinteraction = 0.11 and Pinteraction = 0.36, respectively) [51]. 
Radial as compared with femoral access was shown to have 
consistent benefit across the whole spectrum of patients with 
ACS, resulting in upgrading recommendation as Class I in 
2017 ESC guidelines.
In Japan, the TEMPURA trial randomized patients with 
AMI undergoing primary PCI to transradial coronary inter-
vention (TRI) group (n = 77) and transfemoral coronary 
intervention (TFI) group (n = 72) [52]. The success rate of 
reperfusion and the incidence of in-hospital MACE were 
similar in both groups (96.1 and 5.2 vs. 97.1 and 8.3% in 
TRI and TFI groups, respectively). In a sub-study of PRAS-
FIT-ACS including ACS patients with prasugrel, rates of 
periprocedural bleeding, bleeding not related to CABG, 
and puncture site bleeding were consistently lower in the 
TRI group than in the TFI group [53]. More recently, in a 
report from the CREDO-Kyoto AMI registry was published 
[54]. 3662 STEMI patients who had primary PCI by TRI 
(N = 471) or TFI (N = 3191) were analyzed. The prevalence 
of hemodynamically compromised patients (Killip II–IV) 
was significantly less in TRI group than in TFI group (19 
vs. 25%, P = 0.002). Cumulative 5-year incidences of death/
MI/stroke, and major bleeding were not significantly dif-
ferent between the TRI and TFI groups (26.7 vs. 25.9%, 
log-rank P = 0.91, and 11.3 vs. 11.5%, log-rank P = 0.71, 
respectively). After adjustment for confounders, the risks of 
the TRI or TFI group were not significant for both death/MI/
stroke [hazard ratio (HR) 1.15, 95% confidence interval (CI) 
0.83–1.59, P = 0.41] and major bleeding (HR 1.29, 95% CI 
0.77–2.15, P = 0.34), leading to the conclusion that clinical 
outcomes of transradial approach were not different from 
those of transfemoral approach in primary PCI for STEMI 
in the real-world practice.
Recommendations
• Radial access is recommended over femoral access if 
performed by an experienced radial operator.
Thrombus aspiration
In the new guidelines released by the European Society of 
Cardiology in 2017 on the management of patients with 
ST-segment elevation Ml, routine thrombus aspiration was 
downgraded from IIa to III.
A pooled analysis of individual patient data from three 
large randomized trials [Thrombus Aspiration During 
Percutaneous Coronary Intervention in Acute Myocardial 
Infarction (TAPAS), Thrombus Aspiration in ST-Elevation 
Myocardial Infarction in Scandinavia (TASTE), and Trial 
of Routine Aspiration Thrombectomy with PCI Versus 
PCI Alone in Patients with STEMI (TOTAL)] provided 
novel insights about thrombus aspiration for ST-elevation 
MI [55]. By including 18306 patients, the study did not 
show a significant reduction in cardiovascular death when 
thrombus aspiration was compared with standard therapy. 
There were also no differences between thrombus aspiration 
and no thrombus aspiration with respect to stroke or tran-
sient ischemic attack, recurrent Ml, stent thrombosis, heart 
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failure or target vessel revascularization [56]. Although 
routine use of mechanical thrombus aspiration is no longer 
recommended, prior safety concerns regarding the risk 
of stroke could not be confirmed. Because a trend toward 
reduced cardiovascular death and increased stroke or tran-
sient ischemic attack was found in the subgroup of patients 
with high thrombus burden, future studies may want to 
investigate improved thrombus aspiration technologies in 
this high-risk subgroup.
In contrast to the studies mentioned above, earlier studies 
have shown the benefit of thrombus aspiration in primary 
PCI [57, 58].
Evidence from Japan
There are several studies in Japan showing the benefit of 
thrombus aspiration in primary PCI.
In the VAMPIRE study [59], randomizing patients 
with STEMI to primary PCI with (n = 180) or without 
(n = 175) upfront thrombus aspiration. There was a trend 
toward lower incidence of slow or no reflow (primary end 
point-defined as a thrombolysis in myocardial infarction 
flow grade < 3) in patients treated with aspiration versus 
conventional primary PCI (12.4 vs. 19.4%, P = 0.07). Rate 
of myocardial blush grade 3 was higher in the aspiration 
group (46.0 vs. 20.5%, P < 0.001). Aspiration was most 
effective in patients presenting after 6 h of symptoms onset 
(slow flow rate: 8.1 vs. 37.6%, P = 0.01). Patients pre-
senting late after STEMI appear to benefit the most from 
thrombectomy.
In an observational study (n = 3913) by Nakatani et al. 
[60], thrombus aspiration was associated with a lower 
30-day mortality rate in selected patients with high TIMI 
risk scores, an age > or = 70 years, diabetes mellitus, or stent-
ing adjustment for baseline characteristics.
In the latest guidelines of Japanese Circulation Society, 
thrombus aspiration in primary PCI was recommended as 
Class IIa with level of evidence B. Accordingly, thrombus 
aspiration is performed frequently in primary PCI in Japan. 
A comparison of specifications of aspiration device is tab-
ulated in Table 6. From a practical view point, aspiration 
performance, trackability, and pushability are of importance 
when choosing an aspiration catheter [61].
Anzai et al. reported that thrombus aspiration facilitates 
direct stenting without increasing the cost of treatment [62]. 
Thrombus aspiration can be considered followed by direct 
stenting, which will be discussed later.
Recommendations
• Thrombus aspiration can be considered in primary PCI 
in absence of GP IIb/IIIa inhibitors.
Distal protection
The benefit of distal protection using filter device or occlu-
sion balloon has not been confirmed [63, 64]. However, the 
use of distal protection devices can be considered when 
plaque burden is large and there is a high possibility of dis-
tal embolism or no reflow.
Evidences from Japan
Isshiki et al. reported initial clinical experience with Filtrap 
distal protection filter [65]. Filtrap was successfully deliv-
ered and deployed distal to the lesion in 13 of 14 patients 
(93%). Embolic debris was entrapped in 8 (62%) of these 
cases. All patients were free from in-hospital events except 
for one patient with a large anterior acute myocardial 
infarction who received an emergency surgery due to a free 
wall cardiac rupture. In the ASPARAGUS trial (n = 341), 
patients with AMI were randomized to either stenting with 
or without GuardWire Plus [66]. The rates of slow flow 
and no-reflow immediately after PCI were 5.3 and 11.4% 
in the GuardWire Plus and control groups, respectively 
(P = 0.05). Blush score 3 acquisition rates immediately after 
PCI were 25.2 and 20.3% in the GuardWire Plus and con-
trol groups, respectively (P = 0.26), and the rates at 30 days 
after PCI were 42.9 and 30.4%, respectively (P = 0.035). In 
the CANARY pilot trial, near-infrared spectroscopy and 
intravascular ultrasound were performed at baseline, and 
lesions with a maximal lipid core burden index over any 
4-mm length  (maxLCBI4mm) ≥ 600 were randomized to 
PCI with versus without a distal protection filter. Among 
31 randomized lesions with  maxLCBI4mm ≥ 600, there was 
no difference in the rates of periprocedural MI with versus 
without the use of a distal protection filter (35.7 vs. 23.5%, 
P = 0.69). More recently, the VAMPIRE 3 trial randomized 
200 ACS patients who had attenuated plaque with a longitu-
dinal length of ≥ 5 mm by pre-PCI intravascular ultrasound 
to either distal protection (DP) by filter or conventional treat-
ment (CT) [67]. The primary endpoint of no-reflow phenom-
enon occurred in 26.5% of the DP group (n = 98) and 41.7% 
of the CT group (n = 96; P = 0.0261) and the corrected TIMI 
frame count after revascularization was significantly lower 
in the DP group (23 vs 30.5; P = 0.0003). In addition, the 
incidence of in-hospital adverse cardiac events was sig-
nificantly lower in the DP group than in the CT group (0 
vs 5.2%; P = 0.028). Future studies may further elucidate 
whether distal protection is beneficial in selected patient.
In contrast, distal embolic protection during PCI of saphe-
nous vein graft is confirmed in a multicenter randomized 
controlled trial. In the SAFER randomized trial, a composite 
of death, myocardial infarction, emergency bypass, or target 
lesion revascularization by 30 days was observed in 16.5% in 
the control group and 9.6% in the embolic protection device 
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(P = 0.004). This 42% relative reduction in major adverse 
cardiac events was driven by myocardial infarction (8.6 
versus 14.7%, P = 0.008) and “no-reflow” phenomenon (3 
versus 9%, P = 0.02). Clinical benefit was seen even when 
platelet glycoprotein IIb/IIIa receptor blockers were admin-
istered (61% of patients), with composite end points occur-
ring in 10.7% of protection device patients versus 19.4% of 
control patients (P = 0.008). This study demonstrated the 
importance of prevention of distal embolization in saphen-
ous vein graft. Currently available filter devices in Japan are 
tabulated in Table 7.
Recommendations
• Distal protection can be considered in selective cases 
when plaque burden is large and there is a high possibil-
ity of distal embolism or no reflow or cases with myocar-
dial infarction in saphenous vein graft.
Pharmacological intervention for no reflow
In 2017 ESC guidelines [20], using GP IIb/IIIa inhibitors 
as bailout therapy is considered as Class IIa in the event 
of angiographic evidence of a large thrombus, slow- or no-
reflow, although this strategy has not been tested in a rand-
omized trial.
Evidences from Japan
Miyazawa et  al. [68] studied the effect of nicorandil in 
STEMI, randomizing patients with STEMI to nicorandil 
group (n = 35) or control group (n = 35). In nicorandil group, 
2 mg of nicorandil was injected directly into the infarct area 
prior to reperfusion by PCI. With nicorandil infusion, addi-
tional ST elevations without chest pain were observed for 
a few minutes in 94% of cases. However, no ventricular 
fibrillation or ventricular tachycardia occurred. TIMI myo-
cardial perfusion grade 3 was significantly higher in nico-
randil group (40 vs. 17%, P < 0.01). Rates of adverse events 
were similar, however, left ventricular regional wall motion 
score significantly improved in nicorandil group (P < 0.05). 
The effect of nicorandil was pronounced in patients without 
ischemic preconditioning.
Kobatake et al. compared the effects of nitroprusside 
(n = 25) with nicorandil (n = 24) on the slow/no-reflow phe-
nomenon during primary PCI [69]. The degree of improve-
ment in TIMI flow grade (post–pre/pre) and TIMI frame 
count (pre–post/pre) showed that nitroprusside was more 
effective than nicorandil (nitroprusside vs. nicorandil: 
0.88 ± 0.79, 0.37 ± 0.37, P = 0.008; 0.59 ± 0.23, 0.36 ± 0.27, 
P = 0.003, respectively). At 1 year, rate of MACE was not 
significantly different (5/25 vs. 9/24, P = 0.175).
More recently, a network meta-analysis was published 
comparing the effect of 7 intracoronary agents (adenosine, 
anisodamine, diltiazem, nicorandil, nitroprusside, urapidil, 
and verapamil) on the no-reflow phenomenon in patients 
with STEMI undergoing primary PCI, including 41 rand-
omized control trials with 4069 patients [70]. Anisodamine 
(α1 adrenergic receptor antagonist used in the treatment 
of acute circulatory shock in China) was associated with 
improved post-procedural TIMI flow grade, more occur-
rences of ST-segment resolution, and improvement of 
LVEF. The cardioprotective effect of anisodamine conferred 
a MACE-free survival benefit. Additionally, nitroprusside 
was regarded as efficient in improving coronary flow and 
clinical outcomes. Compared with standard care, adenosine, 
nicorandil, and verapamil improved coronary flow but had 
Table 7  Filter devices for 
distal protection commercially 
available in Japan
Company Product name Filter diameter at expan-
sion (mm)
Guidewire compatibil-
ity (inch)
Length (cm)
Nipro Filtrap 3.5 0.014 180
5 0.014 180
6.5 0.014 180
6.5 0.014 300
8 0.014 180
8 0.014 300
Tri-Med Parachute 5 0.014 190
5 0.014 270
6.5 0.014 190
6.5 0.014 270
8 0.014 270
8 0.014 50
8 0.014 190
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no corresponding benefits regarding cardiac function and 
clinical outcomes.
Considering GP IIb/IIIa inhibitors and anisodamine are 
not available in Japan, use of nicorandil or nitroprusside 
prior to reperfusion by primary PCI can be considered 
reasonable.
Recommendations
• Intracoronary injection of nicorandil can be considered 
to bail out in case of slow flow or no-reflow.
Direct stenting
Evidence in favor of direct stenting (stenting without predila-
tion) in patients with STEMI comes from several studies [71]. 
Loubeyre et al. [72] randomized 206 patients with STEMI to 
direct stenting or stent implantation after balloon predilation. 
The composite angiographic [corrected thrombolysis in myo-
cardial infarction (TIMI) frame count, slow-flow/no-reflow or 
distal embolization] endpoint (11.7 vs. 26.9%; P = 0.01) and 
ST-segment resolution (79.8 vs. 61.9%; P = 0.01) were better 
among patients randomized to direct stenting than among those 
randomized to stent implantation after predilation [72]. In the 
Harmonizing Outcomes with Revascularization and Stents in 
Acute Myocardial Infarction (HORIZONS-AMI), direct stent-
ing (n = 698) compared with conventional stenting after predi-
lation (n = 1830) was associated with better ST-segment reso-
lution at 60 min after the procedure (median: 74.8 vs. 68.9%; 
P = 0.01) and lower 1-year rates of all-cause mortality (1.6 
vs. 3.8%; P = 0.01) and stroke (0.3 vs. 1.1%; P = 0.049) [73]. 
The EUROTRANSFER Registry that included 1419 patients 
showed that direct stenting (n = 276) was superior to stent-
ing after predilation in terms of post-procedural TIMI flow 
grade of 3 (94.9 vs. 91.5%; P = 0.02), no-reflow (1.4 vs. 3.4%; 
P = 0.035), ST-segment resolution of > 50% (86.2 vs. 76.3%; 
P = 0.016) and 1-year mortality (2.9 vs. 6.5%; P = 0.047 after 
adjustment for propensity score) [74]. Direct stenting may be 
advantageous over stenting after predilation in several aspects 
including the use of fewer and shorter stents, shorter fluoros-
copy time and less use of contrast media and reduced micro-
vascular dysfunction/obstruction and no-reflow by reduced 
distal embolization. Potential disadvantages of direct stenting 
may include: failure to reach and/or to cross the lesion, stent 
loss, erroneous estimation of stent length, difficulty with stent 
positioning (especially in case of persistent TIMI flow 0–1), 
underexpansion of the stent in an undilatable (i.e., calcified) 
lesion and stent undersizing due to underestimation of vessel 
diameter because of reduced flow [75]. Notwithstanding these 
disadvantages, direct stenting is considered almost as a default 
strategy during primary PCI.
Recommendations
• Direct stenting is recommended in primary PCI.
Balloon angioplasty
The clinical efficacy of balloon angioplasty for STEMI is 
limited due to the relatively high percentage of restenosis 
caused by elastic recoil and late negative remodeling [76]. 
Several studies showed the need for repeat revasculariza-
tion was significantly reduced by the use of coronary stents 
[77–79]. There are also Japanese evidences supporting 
this fact in patients with AMI [80, 81]. Nonetheless, stent 
implantation did not result in lower rates of recurrent myo-
cardial infarction (MI) or death, when compared with bal-
loon angioplasty alone. Subsequently, numerous randomized 
trials demonstrated a further reduction in target lesion 
revascularization (TLR) could be achieved when using 
drug-eluting stents (DES) as opposed to bare-metal stents 
(BMS). Equivalent to studies comparing balloon angioplasty 
with stenting, though, none of these studies demonstrated a 
reduction in recurrent MI or death [82–84]. An important 
limitation of stent usage is a persistent risk of stent thrombo-
sis and/or in-stent restenosis even years after implantation, 
particularly in patient subsets as STEMI [85–90].
Considering stent implantation may even induce no-
reflow and thereby expand infarct size [91–93], it may 
be reasonable to refrain from stenting if coronary flow is 
restored and no significant stenosis persists after thrombus 
aspiration and balloon dilatation. Indeed, recent studies 
have demonstrated it is safe to defer stent implantation in 
the acute phase of STEMI [94, 95]. Considering the absence 
of superiority with regard to hard clinical end points and 
the potential short- and long-term disadvantages of stent 
implantation, angioplasty with a drug coated balloon (DCB) 
without stenting may well serve as a therapeutic strategy of 
choice in STEMI.
The PAPPA pilot study was the first prospective clinical 
trial studying the efficacy and safety of a DCB only strategy 
in primary PCI for STEMI [96]. Additional stenting was 
allowed only in case of type C–F coronary dissection or 
residual stenosis > 50%. All patients were treated with i.v. 
bivalirudin. Of 100 consecutive STEMI patients, 59 patients 
were treated with a DCB only strategy, whereas bail-out 
stenting was required in 41 patients. At 1-year, a total of five 
major adverse cardiac events were reported (5%). Cardiac 
death was seen in two patients, while three patients under-
went TLR. Although in this pilot study the rate of bail-out 
stenting was relatively high, the use of a DCB angioplasty-
only strategy in the setting of primary PCI seems to be a safe 
and feasible treatment modality. Thus far, no angiographic 
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data are available for the use of a DCB only strategy in 
STEMI.
In the INNOVATION study, 114 patients receiving 
primary PCI for STEMI were randomized into deferred 
stenting (DS) or immediate stenting (IS) [97]. In the DS 
group, the primary procedures included thrombus aspira-
tion and balloon angioplasty and the second-stage stent-
ing procedure was scheduled to be performed at 3–7 days 
after primary reperfusion procedure. DS did not signifi-
cantly reduce infarct size (15.0 versus 19.4%; P = 0.112) 
and the incidence of microvascular obstruction (42.6 versus 
57.4%; P = 0.196), compared with IS. However, in anterior 
wall myocardial infarction, infarct size (16.1 versus 22.7%; 
P = 0.017) and the incidence of microvascular obstruction 
(43.8 versus 70.3%; P = 0.047) were significantly reduced 
in the DS group.
The REVELATION trial plans to randomize 120 patients 
presenting with STEMI either to treatment with a DCB or 
DES [98] (NCT02219802). The primary endpoint is non-
inferiority of the functional assessment of the infarct-related 
lesion by FFR at 9 months after initial treatment.
Recommendations
• Currently, primary PCI using balloon-only strategy is not 
recommended over direct stenting.
Pre‑procedural IVUS/OCT
In ESC guideline of myocardial revascularization [99], intra-
vascular imaging is recommended only in case of resteno-
sis and stent thrombosis to detect stent-related mechanical 
problems and to assess and guide PCI in left main stem (IIa).
Identification of culprit lesion
IVUS and OCT detect plaque ruptures in about half of ST-
elevation myocardial infarction. However, the superior reso-
lution and obligatory flushing with OCT sharply outlines 
the rupture cavity and residual fibrous cap fragment to opti-
mize ruptured plaque identification. de Feyter and Ozaki 
previously demonstrated plaque rupture and thrombus were 
more frequently found in ACS than those in stable angina by 
angioscopy, while IVUS failed to discriminate unstable from 
stable plaque [100]. More recently, Kubo et al. reported, 
when compared with the gold standard of angioscopy, OCT 
can identify a thrombus better than IVUS and differentiate 
between red and white thrombus although red thrombus can 
shadow and obscure underlying plaque morphology [101].
While pathological studies reported that plaque erosion 
plays a role in ACS, there was no clear OCT definition of 
plaque erosion previously. While Ozaki and his colleagues 
proposed that OCT-derived intact fibrous cap (IFC-ACS) 
can be plaque erosion for the first time, contrary to ruptured 
fibrous cap (RFC-ACS), distinct culprit lesion characteris-
tics associated with IFC-ACS mechanisms are not identi-
fied by CT angiography or IVUS [102]. OCT has been used 
to monitor changes in thrombus burden when lesions are 
treated with thrombus aspiration or with pharmacotherapy. 
[103, 104].
In addition, combined IVUS–NIRS imaging, in particu-
lar where an increased plaque burden and lipid component 
present, is able to differentiate culprit lesions from non-cul-
prit lesions with a high accuracy in STEMI [105, 106] and 
NSTEMI [107].
Likelihood of distal embolization or periprocedural 
myocardial infarction during stent implantation
Thin-cap fibroatheromas not only cause plaque rupture and 
thrombosis but also contribute to myonecrosis during stent-
ing. Findings associated with perimyocardial infarction are 
greyscale IVUS-attenuated plaques, especially when the 
amount of attenuated plaque is large and begins closer to the 
lumen than to the adventitia; when large virtual histology-
IVUS necrotic core or a virtual histology-thin-cap fibroath-
eroma or similar findings with integrated backscatter-IVUS 
(lipid) or iMap (necrotic core) are present; when an OCT-
thincap fibroatheroma is present; when large lipid-rich 
plaques are detected by OCT or NIRS; or when plaque rup-
ture is detected by IVUS or OCT [108, 109]. However, the 
positive predictive value is poor and one trial [110] did not 
show superiority of distal protection when treating lipid-rich 
plaques. Conversely, the absence of these findings indicates 
a low probability of a peri-myocardial infarction with a high-
negative predictive value.
Recommendations
• IVUS and/or OCT should be considered to detect stent-
related mechanical problems.
• IVUS can be used to assess severity and optimize treat-
ment of unprotected left main lesions.
Stent
Drug‑eluting stents
Several randomized controlled trials of DES versus DES 
reported long-term follow-up in the past year [111–115]. 
The overall picture from these comparisons based on 
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non-inferiority trials suggests that the 1 year and long-term 
outcomes with newer-generation DES is very good without 
notable differences between brands.
In a DES versus DES comparison with 1-year follow-up 
available, the sirolimus-eluting, thin-strut biodegradable-
polymer Orsiro stent was evaluated in the BIOFLOW V 
study (N = 1334) and compared with the durable-polymer 
Xience everolimus-eluting stent (EES). Six percent of 
patients in the Orsiro group and 10% in the Xience group 
met the 12-month primary endpoint of TLF (P = 0.0399). 
It is noteworthy that the Xience stent in the BIOFLOW 
V had higher TLF rate in selected low-risk patients at 
12-month follow-up than in an “all-comers” population at 
2-year follow-up in the previous SORT OUT IV trial (5%) 
[116]. The difference in TLF was primarily driven by a 
difference in target-vessel Ml (4.7 vs. 8.3%), which was 
not explained by differences in definite stent thrombosis 
(0.5 vs. 0.7%) [117].
In the DESSOLVE III randomized, all-comer trial com-
paring bioresorbable polymer MiStent sirolimus-eluting 
stent and durable polymer Xience EES, TLF at 12 months 
occurred 5.8% in the MiStent group and 6.5% in the Xience 
group (Pnon-inferiority = 0.0001). The rate of definite or prob-
able stent thrombosis at 12 months was 0.7 and 0.9% with 
MiStent and Xience, respectively (P = 0.76).
The SENIOR trial randomized elderly patients undergo-
ing PCI to DES or BMS with use of a short duration of 
dual antiplatelet therapy (DAPT for 1 month in elective 
patients, 6 months in patients with ACS). The study found a 
significant reduction in all-cause mortality, Ml, stroke, and 
ischemia-driven target lesion revascularization in the DES 
group [118]. The conclusion is that BMS should no longer 
be preferred to new generation DES when high bleeding risk 
is of concern and shortened duration of DAPT is desired.
In a network meta-analysis in patients with STEMI under-
going primary PCI (12453 patients from 22 trials) [119], 
CoCr-EES was associated with significantly lower rates of 
cardiac death or MI and stent thrombosis than BMS. CoCr-
EES was also associated with significantly lower rates of 
1-year ST than paclitaxel-eluting stents (PES). Sirolimus-
eluting stents (SES) were also associated with significantly 
lower rates of 1-year cardiac death/myocardial infarction 
than BMS. CoCr-EES, PES, and SES, but not zotarolimus-
eluting stents, had significantly lower rates of 1-year target 
vessel revascularization (TVR) than BMS, with SES also 
showing lower rates of TVR than PES. Another network 
meta-analysis with longer follow-up data analyzed twelve 
trials with 9673 patients [120]. Second generation DES was 
associated with significantly lower incidence of definite or 
probable stent thrombosis (OR 0.59, 95% CI 0.39–0.89), MI 
(OR 0.59, 95% CI 0.39–0.89), and TVR at 3 years (OR 0.50: 
95% CI 0.31–0.81) compared with BMS. In addition, there 
was a significantly lower incidence of MACE with second 
generation DES versus BMS (OR 0.54, 95% CI 0.34–0.74) 
at 3 years. Overall, use of second generation DES is encour-
aged; however, an updated network meta-analysis is awaited 
to compare increasing varieties of drug-eluting stents.
Drug‑coated stents
The LEADERS-FREE (Prospective Randomized Compari-
son of the BioFreedom Biolimus A9 Drug-Coated Stent ver-
sus the Gazelle Bare-Metal Stent in Patients at High Bleed-
ing Risk) study compared the polymer-free biolimus-eluting 
Biofreedom stent with a bare metal stent (BMS) in a cohort 
(N = 2466) at high risk of bleeding. In a subgroup analy-
sis of 659 ACS patients, treatment with the BioFreedom 
stent remained more effective (clinically driven target-lesion 
revascularization 3.9 vs. 9.0%, P = 0.009) and safer (cumu-
lative incidence of cardiac death, Ml, or definite or prob-
able stent thrombosis 9.3 vs. 18.5%, P = 0.001), driven by 
significantly lower rates of cardiac mortality (3.4 vs. 6.9%, 
P = 0.049) and Ml (6.9 vs 13.8%, P = 0.005) [121].
These results confirm the clinical utility of the drug-
coated stents for patients at high bleeding risk and a direct 
comparison with current generation DES would be of great 
interest.
Evidence from Japan
There are scarce randomized studies comparing stents in 
Japan. Sawada et al. randomized patients with STEMI to 
receive EES (n = 23) or SES (n = 12) and compared arte-
rial healing by OCT [122]. Both the EES and SES showed 
an excellent suppression of neointimal proliferation in the 
culprit lesion. The frequency of uncovered and malapposed 
struts of EES was significantly lower than that of SES (2.7 
vs. 15.7%, P < 0.0001, 0.7 vs. 2.3%, P < 0.0001, respec-
tively). EES may promote better arterial healing response 
than SES in patients with STEMI. In the RESET all-comer 
trial, patients were assigned to either EES (n = 1596) or SES 
(n = 1600) [123]. At 3 years, EES was noninferior to SES 
on the primary safety end point (all-cause death or myocar-
dial infarction; 10.1 versus 11.5%; noninferiority P < 0.001; 
and superiority P = 0.19). Cumulative incidence of definite 
stent thrombosis was low and was not significantly different 
between the 2 groups (0.5 versus 0.6%; P = 0.81). The NAU-
SICA trial randomized patients with STEMI to Nobori bioli-
mus A9 eluting stent (BES) or BMS and aimed to compare 
MACE at 1 year. However, the main result has not yet been 
published. In the NEXT randomized trial, patients scheduled 
for PCI using DES were randomized to Nobori biodegrada-
ble polymer BES (1617 patients) or Xience durable polymer 
EES (1618 patients) without any exclusion criteria [124]. At 
3 years, the primary safety end point of death or myocardial 
infarction occurred in 159 patients (9.9%) in the BP-BES 
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group and in 166 patients (10.3%) in the DP-EES group, 
demonstrating noninferiority of BP-BES relative to DP-EES 
(Pnoninferiority < 0.0001 and Psuperiority = 0.7).
Recommendations
• Stenting with new-generation DES is recommended over 
BMS for primary PCI.
Post‑procedural IVUS/OCT
Post-procedural IVUS/OCT is used to evaluate stent under-
expansion, malapposition, tissue protrusion, dissection, geo-
graphic miss and thrombus.
In the IVUS-XPL trial [125], 1400 patients with long 
lesions were randomized to IVUS versus angiographic guid-
ance. IVUS guidance was associated with a lower MACE 
rate of 2.9 versus 5.8% (P = 0.007). In CLI-OPCI observa-
tional study (n = 670), OCT guidance was associated with 
a significantly lower risk of cardiac death or MI as com-
pared to angiographic only guidance [adjusted OR = 0.49 
(0.25–0.96), P = 0.037]. Intravascular imaging-guided PCI 
has a potential to reduce cardiac death, major adverse car-
diac events, stent-thrombosis, and target lesion revasculari-
zation as compared with angiography-guided PCI [126]. 
OCT-guided PCI is non-inferior to IVUS-guided PCI in 
terms of stent expansion in the ILUMIEN III trial [127] and 
clinical outcome in the OPINION trial [128] from Japan.
In general, a small edge dissection found on OCT which is 
undetected on angiography most likely does not have a clini-
cal impact [129–132]. However, the following factors need 
to be considered: longitudinal and circumferential extension 
of dissection, and the depth of dissection (intima, media or 
even adventitia). In the ILUMIEN III [127], edge dissections 
were categorized as major if they constituted ≥ 60° of the 
circumference of the vessel at the site of dissection and/or 
were ≥ 3 mm in length. In this trial, when the intra-dissection 
lumen area is < 90% of the respective reference area, addi-
tional stent implantation was considered. In CLI-OPCI-II trial 
[133], dissection was defined on OCT as a linear rim of tissue 
with a width of ≥ 0.2 mm and a clear separation from the ves-
sel wall or underlying plaque. In this retrospective multicenter 
registry, the acute dissection in the distal stent edge was an 
independent predictor for major adverse cardiac events.
If the malapposition distance from the endoluminal 
lining of strut to the vessel wall is < 250 µm, such struts 
likely become in contact with vessel wall at follow-up. 
Therefore, such small malapposition may be less relevant 
[134, 135]. The clinical relevance of acute malapposition 
on stent failure is not yet fully established [133, 136–138]. 
Ozaki et al. reported the fate of stent malapposition with 
serial (post and 10 months follow-up) OCT examinations 
[139]. They found that of the 4320 struts in 616 slices in 32 
patients with sirolimus eluting stent (SES), persistent malap-
position (incomplete stent apposition; ISA) was observed 
in 4.67%, resolved/healed malapposition was 2.48%, late 
acquired malapposition was 0.37% and most of them was 
well apposed with neointimal coverage in 84.89% and with-
out coverage in 7.59% [139]. More interestingly, thrombus 
was visualised in 20.6% of struts with ISA at follow-up and 
in 2.0% of struts with good apposition (P < 0.001) [139]. 
The temporal evolution and disappearance of malapposition 
made the investigation of clinical relevance of strut malap-
position more complicated.
Recommendations
• IVUS or OCT can be used to optimize stent implantation.
• Acute incomplete stent apposition with a distance 
of ≤ 250 µm is likely to be resolved at follow-up. Addi-
tional post-dilatation is considered when malapposition 
distance is > 250 µm.
• Most edge dissection detected on OCT is clinically silent, 
whereas additional stenting may be performed if the 
width of distal edge dissection is ≥ 200 µm [133].
Mechanical hemodynamic support
IABP counterpulsation is the most widely used mechanical 
support for the treatment of cardiogenic shock, based on the 
beneficial effect of aortic diastolic inflation and rapid systolic 
deflation, improving myocardial and peripheral perfusion and 
reducing afterload and myocardial oxygen consumption.
The previous ESC guidelines stated that intra-aortic bal-
loon pumping may be considered in cardiogenic shock after 
STEMI (IIb) [21]. However, IABP counterpulsation does not 
improve outcomes in patients with STEMI and cardiogenic 
shock without mechanical complications [23, 140], nor does 
it significantly limit infarct size in those with potentially 
large anterior MIs [22]. The latest ESC guidelines no longer 
recommend routine IABP counterpulsation in cardiogenic 
shock except selected patients (i.e. severe mitral insuffi-
ciency or ventricular septal defect).
In other countries, mechanical LV assist devices 
(LVADs), including percutaneous short-term mechanical 
circulatory support devices (i.e. intra-cardiac axial flow 
pumps and arterial-venous extracorporeal membrane oxy-
genation), have been used in patients not responding to 
standard therapy, including inotropes, fluids, and IABP, but 
evidence regarding their benefits is limited [141]. A small 
exploratory trial studying the Impella CP percutaneous cir-
culatory support device did not find any benefit compared 
with IABP in AMI complicated by cardiogenic shock [142]. 
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Therefore, short-term mechanical circulatory support may 
be considered as a rescue therapy to stabilize the patients 
and preserve organ perfusion (oxygenation) as a bridge to 
recovery of myocardial function, cardiac transplantation, or 
even LV assist device destination therapy on an individual 
basis [143, 144].
A structured approach to determine the best adjunctive 
mechanical circulatory support device requires understand-
ing the mechanisms, technical requirements, and hemody-
namic responses of each device [145] (Table 8). Device 
escalation is often required if the initial support device 
(usually IABP) does not improve hemodynamics and end 
organ perfusion. Venoarterial extracorporeal membrane 
oxygenation (VA-ECMO) is often used in a combination 
with IABP to reduce the afterload increased by the retro-
grade flow. In a retrospective cohort study using propen-
sity score matching in the Japanese Diagnosis Procedure 
Combination national inpatient database [146], all-cause 
28-day mortality and in-hospital mortality were significantly 
lower in the IABP combined with VA-ECMO group than 
the VA-ECMO-alone group (48.4 vs 58.2%; P = 0.001 and 
55.9 vs 64.5%; P = 0.004, respectively). The proportion of 
patients weaned from VA-ECMO was significantly higher 
in the IABP combined with VA-ECMO group than in the 
VA-ECMO-alone group (82.6 vs 73.4%; P < 0.001).
There have been several clinical reports suggesting the 
combined use of Impella with IABP [147, 148]. However, 
this combination may decrease Impella forward flow dur-
ing diastole due to diastolic pressure augmentation from the 
IABP [149].
The latest guidelines for STEMI from Japanese Circula-
tion Society recommended IABP use as Class I with level 
of evidence B, considering the percutaneous LVADs were 
not broadly available in Japan. However, the Impella 2.5 
and Impella 5.0 heart pumps received Pharmaceuticals and 
Medical Devices Agency (PMDA) approval from the Japa-
nese Ministry of Health, Labor and Welfare (MHLW) in 
September 2016 and received reimbursement, effective as of 
September 2017. Proper selection of patients, institutional 
criteria are being reviewed in J-PVAD (http://j-pvad.jp).
Recommendations
• Routine intra-aortic balloon pumping is not indicated.
• Intra-aortic balloon pumping should be considered in 
patients with hemodynamic instability/cardiogenic shock 
due to mechanical complications.
• In patients presenting refractory shock, short-term 
mechanical support (Impella or ECMO) may be consid-
ered.
DAPT in maintenance phase
Risk stratification for bleeding
The PRECISE-DAPT score (age, creatinine clearance, 
hemoglobin, white-blood-cell count, and previous sponta-
neous bleeding) was derived from 14963 patients treated with 
Table 8  Comparison of 
mechanical circulatory support 
system. Modified from Atkinson 
et al. [145]
Ao aorta, IABP intra-aortic balloon pump, LA left atrium, LV left ventricle, LVEDP left ventricular end 
diastolic pressure, RA right atrium, PCWP pulmonary capillary wedge pressure, VA-ECMO venoarterial 
extracorporeal membrane oxygenation
IABP IMPELLA VA-ECMO
Cardiac flow 0.3–0.5 L/min 1–5 L/min (Impella 2.5, Impella 
CP, Impella 5)
3–7 L/min
Mechanism Aorta LV → Ao RA → Ao
Maximum implant days Weeks 7 days Weeks
Sheath size 7–8 Fr 13–14 Fr
Impella 5.0–21 Fr
14–16 Fr Arterial
18–21 Fr Venous
Femoral artery size > 4 mm Impella 2.5 and CP: 5–5.5 mm
Impella 5: 8 mm
8 mm
Cardiac synchrony or stable rhythm Yes No No
Afterload ↓ ↓ ↑ ↑ ↑
Mean arterial pressure ↑ ↑ ↑ ↑ ↑
LVEDP ↓ ↓ ↓ ⟷
PCWP ↓ ↓ ↓ ⟷
LV preload – ↓ ↓ ↓
Coronary perfusion ↑ ↑ –
Myocardial oxygen demand ↓ ↓ ↓ ⟷
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different duration of DAPT (mainly aspirin and clopidogrel) 
after coronary stenting and showed a c-index for out-of hospi-
tal TIMI major or minor bleeding of 0.73 (95% CI 0.61–0.85) 
[150]. A longer DAPT duration significantly increased bleed-
ing in patients at high risk (score ~ 25), but did not in those 
with lower bleeding risk profiles, and exerted a significant 
ischemic benefit only in this latter group. As stated in the 
new ESC/EACTS Consensus document on DAPT, the use 
of risk scores such as PRECISE-DAPT designed to evaluate 
the benefits and risks of different DAPT durations ‘may be 
considered’ to support decision making [151].
Recently, Yoshikawa et al. reported that, in a pooled 
cohort of three studies conducted in Japan (12223 patients 
from the CREDO Kyoto registry cohort-2, RESET and 
NEXT), the DAPT score successfully stratified ischemic 
and bleeding risks, although the ischemic event rate was 
remarkably low even in high DAPT score [152].
DAPT duration
Recommendations on duration of DAPT in patients with 
ACS and after elective stenting have been given in the 
ESC/EACTS focused update on DAPT (Fig. 1) [151]. 
Recently, the 2 year follow-up report of the Is There a Life 
for DES After Discontinuation of Clopidogrel (ITALIC) 
study (N = 2031) confirmed the 1-year results and showed 
that patients receiving 6-month DAPT after PCI with 
second-generation DES have similar outcomes to those 
receiving 24-month DAPT [153].
Another study pooled patient-level data from 6 rand-
omized controlled trials and investigated the efficacy and 
safety of long-term (≥ 12 months) versus short-term (3 or 
6 months) DAPT with aspirin and clopidogrel after PCl 
[154]. Of 9577 patients included in the pooled dataset for 
whom procedural variables were available, 1680 (17.5%) 
underwent complex PCI. Overall, 85% of patients received 
new-generation DES. At a median follow-up time of 
392 days, patients who underwent complex PCI had a higher 
risk of MACE [(HR) 1.98; 95% (CI) 1.50–2.60; P < 0.0001]. 
Compared with short-term DAPT, long-term DAPT yielded 
significant reductions in MACE in the complex PCI group 
(adjusted HR 0.56; 95% CI 0.35–0.89) versus the noncom-
plex PCI group (adjusted HR 1.01; 95% CI 0.75–1.35; P 
for interaction = 0.01). The magnitude of the benefit with 
long-term DAPT was progressively greater per increase in 
procedural complexity. Long-term DAPT was associated 
with increased risk for major bleeding, which was similar 
between groups [154]. Results were consistent by per-treat-
ment landmark analysis and further establish procedural 
complexity is an important parameter to take into account 
in tailoring upfront duration of DAPT [151].
A large individual patient data pairwise and network 
meta-analysis comparing short-term (≤ 6 months) versus 
long-term (1-year) DAPT as well as 3 versus 6-month versus 
1-year DAPT included 11473 patients [155]. The primary 
study outcome was the 1-year composite risk of Ml or defi-
nite/probable stent thrombosis. Six trials including 11473 
randomized patients in which DAPT after DES consisted of 
aspirin and clopidogrel: 6714 (58.5%) had stable CAD and 
4758 (41.5%) presented with ACS, the majority of whom 
(67.0%) had unstable angina. In ACS patients, ≤ 6-month 
DAPT was associated with non-significantly higher 1-year 
rates of Ml or stent thrombosis compared with 1-year DAPT 
(HR 1.48, 95% CI 0.98–2.22), whereas in stable patients, the 
rates of Ml and stent thrombosis were similar between the 
two DAPT strategies (HR 0.93, 95% CI 0.65–1.35). By net-
work meta-analysis, 3-month DAPT, but not 6-month DAPT, 
was associated with higher rates of Ml or stent thrombosis 
in ACS, whereas no significant differences were apparent in 
stable patients. Short DAPT was associated with lower rates 
of major bleeding compared with 1-year DAPT, irrespective 
of clinical presentation. All-cause mortality was not signifi-
cantly different with short versus long DAPT in both patients 
with stable CAD and ACS [155].
Regarding long-term antiplatelet therapy, the PEGASUS-
TIMI 54 trial examined two doses of ticagrelor (60 and 
90 mg b.i.d.) vs. placebo in patients with a history of MI 
1–3 years previously. The two ticagrelor doses each reduced, 
as compared with placebo, the rate of the efficacy endpoint 
(cardiovascular death, myocardial infarction, or stroke) with 
Kaplan–Meier rates at 3 years of 7.85% in the group that 
received 90 mg of ticagrelor b.i.d, 7.77% in the group that 
received 60 mg of ticagrelor b.i.d., and 9.04% in the pla-
cebo group [hazard ratio for 90 mg of ticagrelor vs. placebo, 
0.85; 95% confidence interval (CI) 0.75–0.96; P = 0.008; 
hazard ratio for 60 mg of ticagrelor vs. placebo, 0.84; 95% 
CI 0.74–0.95; P = 0.004]. The 60 mg (but not the 90 mg) 
ticagrelor (plus aspirin) regimen also significantly reduced 
the stroke risk compared with aspirin monotherapy. The tica-
grelor regimen was associated with a significantly increased 
bleeding risk. Patients with previous STEMI comprised 
more than 50% of the overall PEGASUS-TIMI 54 popula-
tion, and subgroup analysis has shown consistent results in 
patients with previous STEMI vs. NSTEMI. Extension of 
DAPT beyond 1 year (up to 3 years) in the form of aspirin 
plus ticagrelor 60 mg b.i.d. may be considered in patients 
who have tolerated DAPT without a bleeding complication 
[156].
The studies mentioned above support the concept that 
duration of DAPT should be individualized as discussed in 
detail in the ESC/EACTS DAPT Consensus document [151].
Evidence from Japan
In the STOPDAPT prospective multi-center, single-
arm study (n = 1525), 3-month DAPT after CoCr-EES 
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implantation was compared with the prolonged DAPT regi-
men adopted in the historical control group from the RESET 
trial, where nearly 90% of patients had continued DAPT 
at 1 year [157]. A composite of cardiovascular death, MI, 
stroke, definite stent thrombosis and TIMI major/minor 
bleeding at 1 year occurred in 2.8 versus 4.0%, respectively 
(P = 0.06), and 3-month DAPT was considered at least as 
safe as the prolonged DAPT regimen. Interaction of acute 
myocardial infarction was not significant in the subgroup 
analysis (Pinteraction = 0.65).
Fig. 1  Algorithm for dual antiplatelet therapy (DAPT) in patients 
treated with percutaneous coronary intervention. High bleeding risk 
is considered as an increased risk of spontaneous bleeding during 
DAPT (e.g. PRECISE-DAPT score ≥ 25). Colour-coding refers to 
the ESC Classes of Recommendations (green = Class I; yellow = IIa; 
orange = Class IIb). Treatments presented within the same line are 
sorted in alphabetic order, no preferential recommendation unless 
clearly stated otherwise. 1After PCI with DCB, 6-month DAPT 
should be considered (Class IIa B). 2If patient presents with Stable 
CAD or, in case of ACS, is not eligible for a treatment with prasugrel 
or ticagrelor. 3If patient is not eligible for a treatment with prasugrel 
or ticagrelor. 4If patient is not eligible for a treatment with ticagrelor. 
ACS acute coronary syndrome, BMS bare-metal stent, BRS bioresorb-
able vascular scaffold, CABG coronary artery bypass graft surgery, 
DCB drug-coated balloon, DES: drug-eluting stent, PCI percutane-
ous coronary intervention, Stable CAD stable coronary artery disease. 
Reproduced with permission from Valgimigli et al. [151]
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In the NIPPON trial (n = 3773), non-inferiority of net 
adverse clinical and cerebrovascular events (NACCE) (all-
cause mortality, myocardial infarction, stroke, and major 
bleeding) of 6-month DAPT was shown as compared to 
18-month DAPT following implantation of a Nobori DES 
with a biodegradable abluminal coating [158]. DAPT may 
be shortened according to patient’s ischemic and bleeding 
risks; however, these results should be interpreted with cau-
tion since the population in these trials was not limited to 
patients with acute myocardial infarction.
Recommendations
• DAPT in the form of aspirin plus prasugrel, clopidogrel 
or ticagrelor (e.g. clopidogrel should be used, if prasugrel 
or ticagrelor are not available or are contraindicated), is 
recommended for 12 months after PCI, unless there are 
contraindications such as excessive risk of bleeding.
• A PPI in combination with DAPT is recommended in 
patients at high risk of gastrointestinal bleeding.
• In patients with an indication for oral anticoagulation, 
oral anticoagulants are indicated in addition to antiplate-
let therapy.
• In patients who are at high risk of severe bleeding com-
plications, discontinuation of P2Y12 inhibitor therapy 
after 6 months should be considered.
• In STEMI patients with stent implantation and an indi-
cation for oral anticoagulation, triple therapy should 
be considered for 1–6 months (according to a balance 
between the estimated risk of recurrent coronary events 
and bleeding).
• In patients with LV thrombus, anticoagulation should 
be administered for up to 6 months guided by repeated 
imaging.
• The use of ticagrelor or prasugrel is not recommended 
as part of triple antithrombotic therapy with aspirin and 
oral anticoagulation.
Treatment of non‑infarct‑related artery
General recommendation in revascularization 
of non‑infarct‑related artery in acute MI
Management of non-infarct-related coronary arteries after 
primary PCI for ST-segment elevation Ml remains contro-
versial. In the new guidelines released by the European Soci-
ety of Cardiology in 2017 on the management of patients 
with ST-segment elevation Ml, complete revascularization 
for ST-segment elevation Ml patients with multivessel dis-
ease (MVD) was upgraded from III to IIa with level of evi-
dence A.
In the Compare-Acute trial, 885 patients with ST-segment 
elevation Ml and MVD who underwent primary PCI were 
randomized in a 1:2 fashion to complete revascularization 
of non-infarct-related coronary arteries guided by FFR or 
no revascularization of non-infarct-related coronary arter-
ies [159]. There was a significant reduction in MACCE at 
1 year with FFR-guided complete revascularization (8 vs. 
21%; P < 0.001). The benefit was mostly driven by a reduced 
risk of revascularization. Meta-analyses published so far on 
the topic do not incorporate the results of this study. In one 
of them focusing on the issue of timing for PCI of non-
culprit artery lesions, which encompassed a total of 10 tri-
als with 2285 patients, the reduction in the risk of cardio-
vascular events was observed irrespective of the timing of 
non-infarct-related coronary artery revascularization [160]. 
These results are thus in line with the 2017 ESC guidelines 
on ST-elevation Ml recommending ischemia-guided full 
revascularization [20].
In the setting of cardiogenic shock, the efficacy and 
safety of treating non-infarct-related coronary arteries in 
the context of primary PCI has been a matter of debate. 
In the Culprit Lesion Only PCI versus Multivessel PCI in 
Cardiogenic Shock (CULPRIT-SHOCK) trial (N = 706), the 
30-day risk of a composite of death or severe renal failure 
leading to renal-replacement therapy was lower in patients 
who underwent initial PCI of the culprit lesion only com-
pared with those who underwent immediate multivessel PCI 
[161]. In 2017 ESC guidelines, published 2 months before 
the publication of CULPRIT-SHOCK trial, Grade IIa recom-
mendation with level of evidence C was applied for complete 
revascularization in ST-segment elevation Ml at patients 
with MVD who present with cardiogenic shock.
Recommendations
• Routine revascularization of non-infarct-related artery 
(non-IRA) lesions should be considered in STEMI 
patients with multivessel disease before hospital dis-
charge (either immediate or staged).
• Non-IRA PCI during the index procedure may be con-
sidered in patients with cardiogenic shock.
Physiological assessment of non‑infarct‑related 
artery
FFR has been documented as a valuable tool to guide 
coronary intervention. The adenosine-free index, iFR, has 
emerged as a potential alternative to FFR. The Functional 
Lesion Assessment of Intermediate Stenosis to Guide Revas-
cularisation (DEFINE-FLAIR) [162] (N = 2492) and Instan-
taneous Wave-free Ratio versus Fractional Flow Reserve in 
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Patients with Stable Angina Pectoris or Acute Coronary 
Syndrome (iFR-Swedeheart) [163] (N = 2038) clinical trials 
both examined if iFR was non-inferior to FFR for PCI guid-
ance. The primary end point in both studies was a composite 
of death from any cause, nonfatal Ml or unplanned revascu-
larization at 1-year follow-up. In the DEFINE-FLAIR study, 
the primary end point occurred in 6.8% in the iFR group 
and in 7.0% in the FFR group (P < 0.001 for non-inferiority) 
[162]. In the iFR-Swedeheart study, the primary end point 
occurred in 6.7% in the iFR group as compared to 6.1% in 
the FFR group (P = 0.007 for non-inferiority). Moreover, 
iFR was associated with shorter procedural time and less 
procedural discomfort [163].
Recently, Quantitative flow ratio (QFR) was developed as 
an image-based index for estimating fractional flow reserve 
(FFR). In a retrospective, observational study conducted in 
Japan (n = 142) [164], QFR had good correlation (r = 0.80, 
P < 0.0001) and agreement (mean difference: 0.01 ± 0.05) 
with FFR. After applying the FFR cut-off ≤ 0.8, the overall 
accuracy rate of QFR ≤ 0.8 was 88.0%. On receiver-oper-
ating characteristics analysis, the area under the curve was 
0.93 for QFR. In contrast, 3-D QCA-derived anatomical 
indices had insufficient correlation with FFR and diagnostic 
performance compared with QFR. An observational study to 
investigate diagnostic performance of QFR in comparison to 
FFR in intermediate stenosis in STEMI patients is on-going 
(NCT02998853).
In addition to FFR, iFR, QFR and CT-FFR could be use-
ful tools to decide the treatment indication of non-infarct-
related artery.
Recommendations
• Physiological assessments should be considered before 
performing staged PCI in non-infarct-related artery.
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